News & Updates

Pembrolizumab has demonstrated durable efficacy and a manageable adverse event (AE) profile in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib in a 5-year follow-up of the KEYNOTE-224 study.

Among patients with endometrial cancer (EC), central nervous system metastasis (CNSm) is strongly associated with poor prognoses and survival outcomes, a recent study has found.

In patients with intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), intravesical chemohyperthermia (CHT) does not translate to better cancer control than standard room-temperature chemotherapy, according to a recent phase II study HIVEC-II.

In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.

Genetic predisposition to smoking does not appear to play an important role in the development of endometrial cancer, a study reports.

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

The use of spleen pull-out lymph node dissection in the splenic hilum is both safe and feasible for patients with gastric cancer undergoing radical gastrectomy, a recent study has found.

Low serum albumin levels appear to be an important risk factor for poor survival outcomes among patients with metastatic cervical cancer, a recent study has found.

In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.